Spruce Biosciences, Inc. Common Stock Cash Flow-to-Debt Ratio
Spruce Biosciences, Inc. Common Stock cash flow-to-debt ratio. Spruce Biosciences, Inc. Common Stock (SPRB) has a Cash Flow-to-Debt Ratio of -1.16x as of June 2026, meaning its operating cash flow of $-22.12 Million could theoretically repay -1% of its total liabilities ($19.12 Million) in one year. See financial flexibility index of Spruce Biosciences, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Spruce Biosciences, Inc. Common Stock (2018–2025)
Cash flow-to-debt ratio of Spruce Biosciences, Inc. Common Stock from 2018 to 2025. Historical debt coverage capacity for Spruce Biosciences, Inc. Common Stock across 8 annual periods. Check SPRB cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Spruce Biosciences, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2018–2025)
Spruce Biosciences, Inc. Common Stock cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Spruce Biosciences, Inc. Common Stock. For the full cash flow conversion analysis, see SPRB cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.17x | $-33.33 Million | $10.51 Million | ▲ +7.1% |
| 2024 | -3.41x | $-55.96 Million | $16.39 Million | ▼ -181.6% |
| 2023 | -1.21x | $-33.27 Million | $27.44 Million | ▲ +50.1% |
| 2022 | -2.43x | $-41.68 Million | $17.16 Million | ▼ -2.3% |
| 2021 | -2.37x | $-35.88 Million | $15.12 Million | ▼ -16.1% |
| 2020 | -2.05x | $-27.52 Million | $13.46 Million | ▼ -472.7% |
| 2019 | -0.36x | $-12.62 Million | $35.33 Million | ▲ +5.9% |
| 2018 | -0.38x | $-8.57 Million | $22.58 Million | — |